GFL Environmental Shares Slide After Board Rejects C$52 Buyout Offer
GFL Environmental ended its strategic review without a sale after rejecting a $52-per-share private-equity offer, removing a potential takeover premiu…
AstraZeneca’s Omniose Acquisition Signals Continued Appetite for Preclinical Biotech Deals
AstraZeneca’s acquisition of Omniose highlights its pipeline-building strategy and the pharmaceutical sector’s continued interest in preclinical biote…
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Zura Bio Plunges 76% After Tibulizumab Fails Phase 2 Hidradenitis Trial
Zura Bio shares plunged 76% after tibulizumab failed a Phase 2 hidradenitis trial, prompting the company to discontinue …
Vir Biotechnology’s Positive Phase 3 Hepatitis Delta Data Put $VIR in Focus
Vir Biotechnology’s positive Phase 3 ECLIPSE 1 readout may strengthen its regulatory outlook, but approval and valuation…
Eli Lilly’s Foundayo Sleep Apnea Results Set Up 2026 FDA Filing
Positive late-stage sleep apnea data could broaden Eli Lilly’s Foundayo franchise beyond weight management, with a U.S. …
RBC Initiates Eupraxia Coverage With Outperform Rating as Analysts Cite EP-104GI Data
RBC begins coverage of Eupraxia with an Outperform rating as analysts point to positive Phase 2b EP-104GI data and renew…
Genmab Shares Rise 4% After FDA Approves Partnered Cancer Drug
Genmab shares rose 4% after FDA approval of a Johnson & Johnson-partnered cancer drug, sharpening focus on its oncology …
Novocure Shares Slide After FDA Rejects Optune Mya Brain Metastases Application
Novocure shares were reported lower after the FDA issued a Not Approvable Letter for Optune Mya, clouding the company’s …
Phio Pharmaceuticals Moves PH-762 Toward Phase 2b After Q3 Update
Phio Pharmaceuticals is preparing PH-762 for a potential Phase 2b study as FDA discussions become the next key test for …
Novartis’s Pelacarsen Trial Failure Challenges the Lp(a) Drug Thesis
Pelacarsen’s failed cardiovascular outcomes trial raises questions for Novartis, Lp(a)-targeting therapies and cardiolog…
Pfizer’s Monthly GLP-1 Strategy Could Challenge Lilly and Novo Nordisk
Pfizer’s reported 12% weight-loss result and monthly dosing strategy could reshape expectations for the obesity-drug mar…